World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
Switzerland
2023

D-Index & Metrics

Biology and Biochemistry

D-Index
80
Citations
21516
World Ranking
4115
National Ranking
81

Pascal Furet publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Pascal Furet sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 224 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Pascal Furet D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Pascal Furet sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 80 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Biology and Biochemistry in Switzerland Leader Award

Overview

Pascal Furet is affiliated with Novartis in Switzerland and has contributed extensively to research in biochemistry, genetics, and molecular biology. Their publications span several specialized areas including molecular biology, cell biology, cancer research, materials chemistry, and oncology.

Their research topics focus on multiple key areas, including:

  • Hippo pathway signaling and YAP/TAZ
  • PI3K/AKT/mTOR signaling in cancer
  • Cancer, hypoxia, and metabolism
  • Fibroblast growth factor research
  • Kruppel-like factors research
  • Cancer-related molecular pathways
  • Cancer research and treatments

Furet has published in various scientific journals, with frequent contributions to the following venues:

  • Journal of Medicinal Chemistry
  • ChemMedChem
  • Nature Communications
  • Journal of Chemical Information and Modeling
  • The FASEB Journal

Their recent papers include:

  • "Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4," 2020, Journal of Medicinal Chemistry
  • "p53 dynamics vary between tissues and are linked with radiation sensitivity," 2021, Nature Communications
  • "The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition," 2022, ChemMedChem
  • "Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor," 2022, Journal of Medicinal Chemistry
  • "Leveraging Advanced In Silico Techniques in Early Drug Discovery: A Study of Potent Small-Molecule YAP-TEAD PPI Disruptors," 2023, Journal of Chemical Information and Modeling

Frequent co-authors collaborating with Pascal Furet include:

  • Markus Wartmann
  • Joerg Kallen
  • Yannick Mesrouze
  • Patrick Chêne
  • Robin A. Fairhurst

Best Publications

  • Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

    Sauveur-Michel Maira;Frédéric Stauffer;Josef Brueggen;Pascal Furet

  • In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

    Carlos Garcia-Echeverria;Mark Andrew Pearson;Andreas Marti;Thomas Meyer

  • Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

    Vito Guagnano;Pascal Furet;Carsten Spanka;Vincent Bordas

  • The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

    Andrew A. Wylie;Joseph Schoepfer;Wolfgang Jahnke;Sandra W. Cowan-Jacob

  • Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

    Lipika Goyal;Supriya K. Saha;Leah Y. Liu;Giulia Siravegna

  • Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

    Christine Fritsch;Alan Huang;Christian Chatenay-Rivauday;Christian Schnell

  • Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors

    Peter Traxler;Pascal Furet

  • Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

    Doriano Fabbro;Stephan Ruetz;Elisabeth Buchdunger;Sandra W Cowan-Jacob

  • Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

    Pascal Furet;Vito Guagnano;Robin A. Fairhurst;Patricia Imbach-Weese

  • Inhibitors of tyrosine kinases

    Werner Breitenstein;Pascal Furet;Sandra Jacob;Paul William Manley

  • Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

    J. Schoepfer;W. Jahnke;G. Berellini;S. Buonamici

  • Tyrosine kinase inhibitors: From rational design to clinical trials

    Peter Traxler;Guido Bold;Elisabeth Buchdunger;Giorgio Caravatti

  • Nye Imidazokinoliner, fremgangsmåter for fremstilling av slike og farmasøytiske preparater inneholdende slike, samt anvendelse som et farmasøytiske preparat og anvendelse for fremstilling av et farmasøytisk preparat.

    Furet Pascal;Garcia-Echeverria Carlos;Stauffer Frédéric

  • Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases

    Andreas Floersheimer;Pascal Furet;Paul William Manley;Guido Bold

  • Different susceptibility of protein kinases to staurosporine inhibition Kinetic studies and molecular bases for the resistance of protein kinase CK2

    Flavio Meggio;Arianna Donella Deana;Maria Ruzzene;Anna M. Brunati

  • Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

    Carlos García-Echeverría;Patrick Chène;Marcel J. J. Blommers;Pascal Furet

  • New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

    Bold G;Altmann Kh;Frei J;Lang M

  • Imatinib: a selective tyrosine kinase inhibitor.

    P.W. Manley;S.W. Cowan-Jacob;E. Buchdunger;D. Fabbro

  • Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

    Peter Traxler;Guido Bold;Joerg Frei;Marc Lang

  • Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.

    Sandra W. Cowan-Jacob;Gabriele Fendrich;Andreas Floersheimer;Pascal Furet

Frequent Co-Authors

Stefano Ferrari
Stefano Ferrari Veneto Eye Bank Foundation
Doriano Fabbro
Doriano Fabbro Novartis (Switzerland)
Wolfgang Jahnke
Wolfgang Jahnke Novartis (Switzerland)
Wolfgang Froestl
Wolfgang Froestl AC Immune (Switzerland)
Thomas Knöpfel
Thomas Knöpfel Hong Kong Baptist University
Nathanael S. Gray
Nathanael S. Gray Stanford University
William R. Sellers
William R. Sellers Harvard University
Thomas J. Meyer
Thomas J. Meyer University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Pascal Furet

Trending Scientists